Bayer's Kidney Portfolio Delivers on Two Fronts as Wall Street Waits for November Numbers

Bayer's pipeline produced a pair of kidney-disease wins on Thursday, with subgroup analyses from the Phase III FIND-CKD trial showing finerenone holding its own against placebo across distinct patient populations—all in chronic kidney disease without diabetes.

In immunoglobulin A nephropathy (IgAN), proteinuria fell 51% versus placebo, according to company figures presented at ASN Kidney Week 2026. The same dataset pointed to effects on the decline of kidney function across the patient groups studied.

Patients with focal segmental glomerulosclerosis (FSGS) told a similar story over a twelve-month horizon. Albuminuria dropped 40% relative to placebo, while proteinuria declined 41% over the same period. Bayer framed the readouts as kidney-protective effects versus placebo spanning multiple subgroups, with FSGS and IgAN the two highlighted.

Darolutamid Adds a Prostate Cancer Datapoint

Away from the kidney franchise, Bayer released an interim analysis from a Phase III trial of darolutamid, testing the drug in combination with androgen deprivation therapy and radiotherapy in prostate cancer patients at high risk of recurrence. On the combined endpoint of metastases or death, the treatment cut risk by 58% compared with placebo.

Vividion and AskBio Keep the Early Pipeline Moving

Clinical news also arrived from Bayer's subsidiary Vividion Therapeutics, which on October 15 reported dosing of the first patient in a global Phase II study of VVD-214 combined with pembrolizumab. The trial targets previously untreated advanced MSI-high or dMMR colorectal cancer.

AskBio, another Bayer unit, announced five presentations on advances in AAV manufacturing technologies, slated for the ESGCT congress running October 27–30, 2026 in Hamburg.

Analysts Hold Their Ground Ahead of the Quarterly Report

Two brokerage confirmations landed in the run-up to earnings. JPMorgan analyst Richard Vosser reiterated an "Overweight" rating and a EUR 61 price target on October 16, according to media reports—a confirmation rather than an upgrade or downgrade. A day earlier, UBS had likewise reaffirmed its "Buy" call with a EUR 62 target.

Bayer also published a study on global agricultural competition roughly two weeks ago, concluding that the European Union and the United Kingdom risk falling further behind, citing slower growth in crop production than in several major agricultural markets.

The next confirmed financial date is the third-quarter 2026 interim report on November 3, scheduled for 07:30 CET. A media update follows at 10:00, with the investor conference set for 14:00 CET the same day.